Navigation Links
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Date:4/14/2008

Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts

DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613).

Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster highlights data indicating that S-110 showed robust anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Importantly, reduced toxicity was observed along with an increased half-life compared to decitabine.

"S-110's increased half-life, reduced toxicity and improvement of efficacy when compared to decitabine in its currently marketed formulations make it an attractive, next-generation hypomethylator for the treatment of hematoligic malignancies," said Dr. James Manuso, SuperGen's President and CEO. "As we develop S-110 further, we will continue to explore its potential to enhance solid tumors' sensitivity to standard chemotherapy agents, including cisplatin. We look forward to advancing this promising candidate to clinical trials later this year or early next year."

Copies of the 2008 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site http://www.superg
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
6. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... 8, 2011 Elsevier Business Intelligence , ... conferences, is hosting Windhover,s 21 st Pharmaceutical Strategic ... in New York, NY. PSA is the only ... a diverse mix of pharma,s top talent. It,s an opportunity ...
... Medical, a leading manufacturer of integrated medical imaging display and ... year, Carrot Medical achieved significant growth in sales and an ... of 2011 with record second quarter sales, Carrot surpassed its ... company is now well positioned for the third straight year ...
Cached Medicine Technology:Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 2Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 3Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine Course. ... October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. The ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Patients who thought ... those who are interested in learning more about the procedure beyond the information found ... , Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival ... Tuesday, September 1. , “Alive Inside” shadows a social worker who advocates for the ... “It’s a documentary about bringing music to residents in health care centers who may ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden State Urology is ... result of a merger of five of the busiest urology practices in Morris ... more cost-effective and higher quality care than they did individually. Their mission ...
Breaking Medicine News(10 mins):Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2
... is a dramatic shift in attitudes toward circumcision in Swaziland, ... of the practice and one of the highest HIV prevalence ... it is making a sudden comeback in the country since ... practice could reduce the risk of contracting HIV. ...
... of the most frequent New Year resolutions is "I'll quit ... find it hard to keep their good // ... Now an initiative undertaken by the Manchester Evening News, a ... resolution. ,The paper has undertaken this ...
... high as researchers feel that if mutation of the bird flu ... death world wide as the virus could have the capacity to ... in China from spread to poultry of bird flu virus from ... to bird flu recently in the Sanming City. World Health Organization ...
... death sentence. It is the most lethal cancer there is. ... GBM annually in the U.S., half // will ... The treatments include highly invasive surgeries to remove the tumor ... to a very low quality of life. Hence, researchers are ...
... University of Michigan’s researchers has revealed that those children who live ... to put on weight. As many as 16% of those belonging ... are reported to be overweight, while in the UK the number ... early 1990s. ,The researchers, led by Julie Lumeng, ...
... have one more reason to raise a toast- a formula ... you // can pep-up your spirits and relish ... Coventry University, and author of the formula for Marks & ... popping open a champagne bottle. According to smith, P = ...
Cached Medicine News:Health News:Men queue up for Circumcision In Swaziland To Prevent HIV/AIDS 2Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: